MarginsXMarginsX
Home › Markets › Health Care › IKT

Inhibikase Therapeutics Inc. (IKT)

IKT trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.45
-4.61% on the day
Market cap
$203.4M
Micro cap
Revenue · 2024
$0
-100.0% on 2023
Net income · 2024
-$27.5M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/1750149/000095017025046096/0000950170-25-046096-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-12-31.

Profile

FieldValue
TickerIKT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2020
SEC CIK0001750149
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2024

LineValue
Revenue$0
Net income-$27.5M
Operating income-$28.6M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$97.5M
Total assets$98.6M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
12.6 months
$51.7M cash at September 30, 2026
Share count, 1 year
+86.6%
2025-11-07 to 2026-11-02 · +2171.8% over 3 years
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
$3.0M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-10
Cash and burn$51.7M cash; operating cash flow -$12.3M a quarter.Report 2026-09-30
Shares outstanding140,269,633 (2026-11-02); 75,175,306 a year earlier; 6,174,280 three years earlier.Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2025-12-19
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCohnReznick LLP, Holmdel, New Jersey, United States; changed auditors 1 time in 24 months8-K 4.01 2026-08-26
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $3.0M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$20.5M-$17.4M$51.7MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2026
2026-06-30
$0-$19.6M-$12.4M$31.2MNo debt tagsNeeds four quarters10-Q 2026-08-11
Q1 2026
2026-03-31
$0-$16.4M-$12.1M$49.6MNo debt tagsNeeds four quarters10-Q 2026-05-12
Q4 2025
2025-12-31
Not filed-$12.7M-$7.5M$178.8M$0Needs four quarters10-K 2026-03-26
Q3 2025
2025-09-30
$0-$11.9M-$10.6M$38.3M$0$010-Q 2025-11-14
Q2 2025
2025-06-30
$0-$9.9M-$5.6M$77.7M$38K$010-Q 2026-08-11
Q1 2025
2025-03-31
$0-$13.7M-$4.1M$73.4M$75K$010-Q 2026-05-12
Q4 2024
2024-12-31
$0-$12.1M-$5.3M$97.5M$111K$010-K 2025-03-27

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-12-19
Latest annual report10-K2026-03-26
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10
Latest proxyDEFA14A2026-04-30

Source: SEC EDGAR submissions feed, 370 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+1.3%
1 month-13.6%
3 months-36.9%
Year to date-25.9%
1 year-5.0%
From 52-week high-39.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
LCTXLineage Cell Therapeutics Inc.$0.7951-13.07%$201.1M
ARTVArtiva Biotherapeutics Inc.$3.96-1.25%$195.8M
CGENCompugen Ltd.$2.04-2.86%$193.0M
PALIPalisade Bio Inc.$1.03-8.04%$184.7M
CABACabaletta Bio Inc.$1.11-13.28%$239.4M
PLXProtalix BioTherapeutics Inc. (DE)$3.03-0.66%$255.5M
IVVDInvivyd Inc.$0.5377-7.63%$158.5M
OCGNOcugen Inc.$0.7730-6.62%$262.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier